{"entity":{"id":"chu-farhat-hached-sousse","kind":"institution","name":"Centre Hospitalier Universitaire Farhat Hached, Sousse","aka":["CHU Farhat Hached","Farhat Hached University Hospital","Farhat Hached Hospital of Sousse"],"tldr":"A university teaching hospital in Sousse with a radiotherapy service and a breast unit that treats about 350 new breast cancers a year. It is a site for international cancer and blood disorder trials.","summary":"IAEA DIRAC's equipment report, read on 11 November 2026 with the entry last updated in 2023, lists the radiotherapy service of Hôpital Farhat Hached in Sousse with one linear accelerator, one cobalt-60 unit and a CT scanner, and no brachytherapy unit. The Breast Centres Network directory (last modified March 2022) lists its breast unit with about 350 new breast cancer cases a year and a multidisciplinary team of radiologists, surgeons, pathologists, medical oncologists, radiotherapists and nurses, with a European certification in breast surgical oncology valid to 22 November 2026. ClinicalTrials.gov lists it as a site of the trial of inavolisib with pertuzumab and trastuzumab in PIK3CA-mutated HER2-positive breast cancer (NCT05894239) and of the long-term luspatercept safety study (NCT04064060). Its own website did not answer.","asOf":"2026-11-11","links":[{"label":"IAEA DIRAC: radiotherapy centres and equipment (read 11 November 2026)","url":"https://dirac.iaea.org/Data/CountriesLight"},{"label":"Breast Centres Network: F. Hached University Teaching Hospital","url":"https://www.breastcentresnetwork.org/breast-units/directory/Tunisia/F.+Hached+University+Teaching+Hospital+/4,9,42,"},{"label":"ClinicalTrials.gov NCT05894239: site list","url":"https://clinicaltrials.gov/study/NCT05894239"},{"label":"ClinicalTrials.gov NCT04064060: site list","url":"https://clinicaltrials.gov/study/NCT04064060"}],"tags":[],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-salah-azaiez","chu-habib-bourguiba-sfax"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sousse","country":"TN","lat":35.83,"lng":10.628,"institutionType":"hospital","programs":["Radiotherapy (one linear accelerator, one cobalt unit in IAEA DIRAC)","Breast unit (about 350 new cases a year)"]},"route":"/institutions/chu-farhat-hached-sousse/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"institution":[{"id":"chu-habib-bourguiba-sfax","kind":"institution","name":"Hôpital Habib Bourguiba, Sfax","route":"/institutions/chu-habib-bourguiba-sfax/"},{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/"}],"trial":[{"id":"nct04064060","kind":"trial","name":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","route":"/trials/nct04064060/"},{"id":"nct05894239","kind":"trial","name":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","route":"/trials/nct05894239/"}]}}